Agenus, Inc.

Agenus Inc. is a biotechnology company dedicated to developing immunotherapy products for cancer treatment. Founded with a mission to harness the body's immune system to fight cancer, Agenus focuses on creating a broad pipeline of antibody-based therapeutics and vaccine adjuvants. One of the key areas the company excels in is the field of checkpoint inhibitors, which are designed to enhance the immune system's ability to recognize and combat tumor cells. Agenus Inc. also invests significantly in innovative platforms such as its proprietary Retrocyte Display technology, which accelerates antibody discovery and optimization. With a diverse portfolio targeting multiple cancer types, Agenus plays a crucial role in the biopharmaceutical sector by advancing personalized medicine and contributing to the ongoing development of breakthrough cancer therapies. As a part of the health care sector, the company's advancements in immunotherapy provide significant value, offering potential therapeutic avenues and addressing unmet medical needs.